(Reuters) -Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.

Eli Lilly and Company announced on Monday detailed results from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating ...

Novo Nordisk (NYSE:NVO) shares dropped 5% in early trading on Monday after Eli Lilly (NYSE:LLY) released new trial data showing its weight loss drug, Zepbound, delivered stronger results than Wegovy.

Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that ... other incretin medicines for obesity," claims Lilly. The new vials – priced at ...

Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy Zepbound in an expansion ... is available at $399 per month. Lilly claims the single-dose versions cost at least ...

As a Biden administration ban on so-called “junk fees” took effect Monday, Ticketmaster said it would start displaying the ...

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said ...

Lilly sues four telehealth firms for unauthorized compounding of Mounjaro and Zepbound. 2. GLP 1 drugs remain in high demand ...

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

Coleman manages even more money than that $6 billion figure. His Tiger Global Management watches over $46 billion in assets.

While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...